Samsung Biologics Workers Strike Over Pay

Unionized workers at Samsung Biologics — Samsung Biologics America, the biotech arm of Samsung Electronics, initiated their first general strike, lasting five days, to demand higher wages and expanded performance-based compensation. The union seeks a 14 percent increase in pay, a 30 million South Korea — South Korean won cash incentive, and bonuses equivalent to 20 percent of annual operating profit, while Samsung Biologics — Samsung Biologics America has proposed a 6.2 percent increase. Negotiations have been ongoing since December, with 13 rounds failing to bridge the differences. The company filed for a court injunction to block the strike, which was partially upheld, restricting action in three of nine production stages. Samsung Biologics — Samsung Biologics America estimates potential losses from a full-scale strike could exceed 640 billion South Korea — South Korean won, roughly half of its first-quarter sales. CEO John Rim has urged employees to consider the potential irreversible losses. Industry officials warn that disruptions could affect product quality, a critical concern for regulators like the United States — Food and Drug Administration.